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ABSTRACT
Purpose: The scientific knowledge of how genes affect disease expression and evolution
can facilitate more effective environmental and drug therapy interventions delivered by
health care professionals. The purpose of this paper is to a) describe the role of genetic
science in healthcare; b) explore genotype determinants for environmental and
pharmacological interventions; c) and analyze ethical dilemmas, barriers to access, and
allocation of resources based on genotype.
Methods: A review of literature was conducted from the disciplines of nursing, medicine,
psychology, and sociology using the CINAHL, Ebsco Host, Medline, and PsychINFO
databases. The search was limited to peer reviewed, full text article in English that dated
from 1987 to 2011. Inclusion criteria were articles describing environmental,
pharmacologic, and nutritional influence on genetic expression. Forty-five articles on
genetic intervention were chosen for further review, in addition to five book publications
which met inclusion criteria. Many of the sources retrieved were obtained from the
biomedical sciences and published in the last decade, owing to more recent innovations in
genetic discovery.
Results: Disease and treatment must be approached according to genetic profiles for
effectiveness and to increase health outcomes. Several variations were found regarding
response to pharmaceuticals, as well as environmental exposures, based on genotype.
Conclusions: Health care has been practiced using a “universal protocol” approach;
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however, as the literature reveals, each individual genotype must be taken into account to
provide optimal care.
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INTRODUCTION
The emerging science of human genetics is reshaping the way in which diseases are
diagnosed, treated, and prevented. Recent advances in the etiology for the genetic
composition of disease expression and evolution incorporate various relationships
between genetic health, genetic risk, and intervention. In the past, evidence-based practice
has focused on the work of Gregor Johann Mendel, which established disease interventions
based on the expression of single gene locus disorders with simple, genetically attributed
causes (Frazier, Turner, Schwartz, Chapman, & Boerwinkle, 2004). However, diseases are
now being studied and treated under the idea of complexity, which involves multi-factorial
causes. This is because complex diseases, with extreme individual variation, are a public
health concern and consist of more than just standard vulnerability. As the framework
implies, there are genetic components with susceptible alleles, that when combined with
the right triggers, can initiate or exacerbate disease (Frazier et al., 2004). As concluded by
Mendel’s work, the genotype of an individual is made up of many forms and specific
variants of a gene that can be responsible for hereditary variation. An individual’s
phenotype is determined by their genotype. However, genetic disease expression and
evolution is multi-factorial and can be influenced by the lifestyle an individual pursues,
including choice of residence, food preferences, occupation, and personal behaviors the
individual chooses to engage in (D’Amato-Kubiet, 2009).
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Chronic diseases such as cardiovascular disease, cancer, stroke, and diabetes
possess a genetic component. However, environmental factors, including lifestyle and
dietary habits have been known to trigger, accelerate, exacerbate, or prolong onset of
disease (Greco, Prows, Skirton, Williams, Jones, Middleton, Lewis, Bickford, Daley, Seiler,
Carson-Smith, 2007). Response to environmental triggers remains inconsistent from one
individual to another. Genetic variation alone cannot account for disease susceptibility in
some, without environmental and/or behavioral factors. Although it is well known that
disease can be controlled by manipulation of lifestyle and environmental factors, chronic
disease rates are still on the rise. This is because current treatments are based on
standards of care which establish interventions based on epidemiological studies of large
populations, not individuals. As stated by Khoury, Davis, Gwinn, Lindegren, and Yoon
(2005), “our current public health approaches to prevention have not been adequate”.
Therefore, studies that explore the underlying science of the individual gene-environment
interactions is expected to unravel more precise interventions to improve quality of life
(Andreasen & Andersen, 2009). Recently, the genetic basis for drug therapy has been aimed
at uncovering how variations in multiple genes affect the pharmacokinetics and
pharmacodynamics of a drug. Genetic variation among individuals has been found to alter
the therapeutic response to drugs, and can now be linked to adverse reactions or lack of
response to drug therapy. Understanding genetic variation in response to drugs allows
medications to be tailored to individual phenotypes and genetic predispositions, rather
than the use of a universal (standard) protocol that may be less effective or even
2

detrimental to select genotypes. The purpose of this study is to examine barriers and access
to genetic determinants of disease and their impact on lifestyle based interventions. Two
areas of genetic discoveries, ecogenetics and pharmacogenetics, will be examined to
determine their implications for lifestyle interventions and research. The knowledge of
genetics is rapidly expanding; therefore, there is an increased need to explore the types of
interventions available for diagnosing, treating, and preventing disease.
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IMPACT OF GENETIC SCIENCE IN HEALTH CARE
Human Genome Project
Several organizations are extensively exploring human genetics in effort to broaden
our understanding of the role of genetics in the human species, including The Department
of Energy, The National Institutes of Health, and The Center for Disease Control and
Prevention. Of these organizations, The Department of Energy established The Human
Genome Project (HGP), which began in 1990. The results of this project uncovered many
components in the field of genetic variation. The project’s primary purpose was to
understand the genetic makeup of the human species in an effort to develop medicines and
guide decisions in healthcare. The HGP concluded in its results that human beings possess
approximately 20,500 genes (HGIP, 2010). Further genetic research is being conducted to
explore genetic expression and will provide insight into disease etiology and pathogenesis.
Leaders in genetic research propose that disease specific treatments can be developed
based on finding the multi-factorial genetic/genomic components of disease. The Human
Genome Project (2010) focused on genetic variants of more common, major diseases such
as cardiovascular disease, cancer, or diabetes. The results provided the need for greater
amounts of genetic testing for the underlying gene components of disease (HGIP, 2010).
Genetic testing involves the analysis of cells for gene products such as proteins,
enzymes, metabolites, and/or chromosomes (HGPI, 2010). Genetic testing is the precursor
for genomic health care, which is defined as a highly individualized plan of care that utilizes
4

information related to phenotype responses and gene functions (Shives, 2008). The results
of these tests allow early identification of disease susceptibility and treatment with
conventional interventions based on individual genetic variation. Early identification of
disease involving the application of knowledge about genes is accomplished through the
use of reproductive and therapeutic genetic testing interventions. Reproductive genetic
testing interventions are suggested for individuals with a known family history of a genetic
disorder, to guide reproductive decisions. The testing may be performed on persons who
intend to have children, or on the fetus if conception has occurred (Buchanan, Brock,
Daniels, and Wikler, 2000). Therapeutic genetic testing interventions involve tailoring
environments, nutrition, or medication regimens to optimize health and treatment. In both
circumstances, genetic screening for high-risk populations or those with family history will
facilitate early prevention and treatment (Ambler & Brown, 1999). Decisions to pursue
genetic testing can be determined through the use of genetic counseling. Counseling
provides an avenue to assist individuals in understanding, adapting to, and using genetic
information. Genetic counseling addresses concerns of cost, by assisting individuals in
utilizing resources, becoming active consumers, and determining the benefits of treatment
(Greco et al., 2007).
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ENVIRONMENTAL AND PHARMACOLOGICAL INTERVENTIONS
Ecogenetics
The recent movement in molecular science has given significant meaning to the
principle behind ecogenetics that genes form the basis for disease, but are not expressed
unless an environmental trigger is exercised (D’Amato-Kubiet, 2009). Ecogenetics uses
knowledge of how genes work in various environments to predict and intervene on the
basis of genotype. Exploring ecogenetics provides a basis for understanding how genelifestyle interactions enhance our knowledge of disease, design interventions, and
eventually facilitate disease prevention (Pomeroy, Soderberg, & Franks, 2009). When
considering genetic-environmental interactions, it is important to identify the underlying
susceptibility of genes to biologic and physiologic factors. This will give explanation as to
why some individuals develop disease when exposed to environmental agents and how
genetic predisposition may encourage adaptation to environmental exposures (Frazier et
al., 2004). Additionally, understanding how and which environmental stimuli promote
manifestation of disease susceptibility genes will lead to individualized disease prevention
strategies (Frazier et al., 2004).
Genetic research focused on lifestyle interventions is determining which
environmental exposures present disease risk and is using genetic sensitivity to chemical
agents to develop individualized drug therapy plans of care. It will require an integrative
approach using epidemiologists’ future studies of environmental causes of human disease,
6

as more genes and biologic pathways are researched (Khoury et al., 2005). Furthermore,
genetic technology and studies examining large sample groups from defined populations
have strengthened causal interpretation of genetic knowledge of disease expression
(Frazier et al., 2004). Environment-gene interactions can be difficult to accurately measure
or describe because of inconsistent exposure to environmental triggers over time, such as
changes in residence or dietary habits. However, technological tools for measuring casual
gene-environment relationships with exposure overtime are rapidly being developed. For
example, toxicogenomics is being examined to assess the effects of specific chemical
exposures using gene and protein expression as markers (Khoury et al., 2005).
Additionally, rather than examining only genetic causes, it will prove most beneficial to
identify environmental triggers associated with specific genes to better prevent and treat
disease.
Insulin Resistance in Metabolic Syndrome
In a recent study by the American Society for Nutrition, gene-nutrient interactions
were examined to determine susceptibility to metabolic alterations in metabolic syndrome
phenotypes, particularly insulin-resistance. The study’s aim was to analyze the degree of
influence that genetic as well as environmental factors, specifically dietary fat, have on
health outcomes. The interaction between specific alleles of the adiponectin and plasma
saturated fatty acids were evaluated to determine responsiveness to dietary intervention.
Adiponectin plays a major role in regulating insulin sensitivity, and decreased
7

concentrations have been found in metabolic syndrome phenotypes (Ferguson, Phillips,
Tierney, Perez-Martinez,, Defoort, Helal, Lairon, Planells, Shaw, Lovegrove, Gjelstad,
Drevon, Blaak, Saris, Golabek, Wilk, Riserus, Karlstrom, Miranda, & Roche, 2010).) The
study included 451 subjects, all having metabolic syndrome phenotypes. Inclusion criteria
for metabolic syndrome phenotypes consisted of: body mass index of 20-40kg/m, and
required subjects to fulfill ≥ 3 of the following 5 criteria: waist circumference > 102cm
(men) or 88cm (women), fasting glucose 5.5-7.0mmol/L, triacylglycerol ≥ 1.5mmol/L,
cholesterol < 1.0mmol/L (men) or 1.3mmol/L (women), and blood pressure ≥ 130/85 mm
Hg (Ferguson et al., 2010). Genetic analysis tools were then used to identify the presence of
single-nucleotide polymorphisms in the adiponcentin gene, which contribute to the
development of insulin resistance in metabolic syndrome (Ferguson et al., 2010). As shown
in Table 1, the single-nucleotide polymorphisms which showed the greatest interaction
between saturated-fatty acids and alterations in insulin sensitivity were rs266729 and
rs10920533. Individuals homozygous for the minor allele in both single-nucleotide
polymorphisms were found to be more sensitive to an oral fat load and high concentrations
of saturated-fatty acids. Exploration of similar studies suggests there is a relationship
between genetic expression of insulin resistance and dietary intake that is unique to
individuals with diabetes, a component of metabolic syndrome. Personalized nutrition is a
modifiable contributor to lifestyle management that can prevent or mitigate disease
progression since the genotype of these polymorphisms may play a role in the
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responsiveness to dietary fatty acid modification in subjects with metabolic syndrome
(Ferguson et al., 2010).
Environmental Exposure in Children with Fragile X Syndrome
According to Murphy & Abbeduto (2005) developmental theorists studied the role
of genes in behavioral development using transactional analysis as a theoretical
framework. This model provides a method for psychosocial analysis, describing patterns of
childhood development and external influences (Berne, 2001). The theory implies that an
individual’s behavior and characteristics are established by an interaction between one’s
genotype and environmental factors. Within the framework of transactional analysis, a
genetic anomaly is labeled as predisposing an individual to a behavioral phenotype;
however, the environment determines the extent of expression (Murphy & Abbeduto,
2005). To understand the magnitude of environmental influence, a transactional analysis of
behavioral development must be applied to interventions associated with genetic
anomalies. In the example of fragile X syndrome, an X-linked genetic disorder, language
development with difficulty in communication skills, hyperarousal and hypersensitivity to
sensory stimuli are common traits (Murphy & Abbeduto, 2005). Using transactional
analysis, developmental theorists concluded that these syndrome-specific behaviors are
extremely variable and may be prompted more by environmental factors such as anxiety
and arousal than by the severity of the genetic disorder. Therefore, modification of these
environmental factors may optimize levels of arousal and enhance learning ability (Murphy
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& Abbeduto, 2005). However, it must not be overlooked that environmental modifications
used to promote development have the potential to further distinguish the course of the
disorder. Behavior and lifestyle factors, including modifications of surroundings enhance
development by decreasing arousability (Murphy & Abbeduto, 2005). But, these same
modifications may create nonnormative environments, while promoting syndrome-specific
behaviors. In an effort to correct or avoid hyperarousal or overstimulation, the child may
become dependent on the use self-directed behaviors or avoidance of social interaction
(Murphy & Abbeduto, 2005) As a child with fragile X syndrome moves through
developmental stages, the behavioral phenotype may be become more apparent.
Inadvertently, environmental modifications in which the child interacts with may promote
expression, thus decreasing the likelihood of syndrome-specific characteristics diminishing
over time (Murphy & Abbeduto, 2005). The environmental intervention of transactional
analysis focuses on transactions that occur between the child and interactions within their
environment. As shown in Table 1, this approach will assist in identifying
counterproductive transactions, in addition to communication distortions (Berne, 2001).
Ultimately, growth promotion and development in a child with fragile X syndrome, depend
on how the child responds to various environmental input, including responsiveness of
caregivers to syndrome-specific behaviors.
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Traveling Population and Thrombosis Formation
A major area of concern regarding environmental risk factors in genetically
susceptible individuals is the traveling population. When considering the environmental
factor of “economy-class syndrome”, there has been concern as to why some individuals
experience thrombotic events during long duration travel and others do not, given that all
other environmental factors are equal (Sharma & Gohil, 2010). This gap in knowledge led
the researchers to examine the influence of genetic factors on the development of venous
thrombosis. The results found by Sharma & Gohil (2010) identified mutations in the
coagulation Factor V and Factor II [prothrombin G20210A]. A significantly large portion of
individuals with single-nucleotide polymorphisms in one of either gene were found to have
experienced a venous thrombotic event. The study supported its findings through a metaanalysis review of 173 studies. The results as seen in Table 1, were that a genetic
contribution could be attributed to at least 200,000 deaths in one year, associated with a
venous thrombotic event (Sharma & Gohil, 2010). The resultant implications are that
individuals who are at known genetic risk for developing venous thrombosis, combined
with the right environmental stimuli [extended flight], may implement preventative
measures such as using anti-embolism stockings or prophylactic use of selective
anticoagulants (Sharma & Gohil, 2010).
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Table 1: Ecogenetic Interventions in Metabolic Syndrome, Children with Fragile X Syndrome, and The
Traveling Population
Researcher

Population
Studied

Ferguson et
al., (2010)

451 subjects, all
having metabolic
syndrome
phenotypes

Genetic
Alteration
(SNP)
adiponectin
gene

Environmental
Factor

Findings

saturated fatty
acids

Alterations in either
interact with plasma
saturated-fatty acids
to alter insulin
sensitivity. Screening
for polymorphisms in
the adiponectin gene
will help identify those
that would likely
benefit from
modification of dietary
fat intake.

sensory stimuli

Interventions that
focus on transactions
between child &
environment, in
response to sensory
stimulation & sociallyadaptive behaviors
will decrease the
extent of expression.

[rs266729]
[rs10920533]

Murphy &
Abbeduto
(2005)

children of fragile X
syndrome

X -chromosome

anxiety

Berne
(2001)

arousal
(transactional
analysis)

Sharma &
Gohil
(2010)

traveling
population

coagulation
factor V

extended flights

factor II
(prothrombin
G20210A)

Individuals with either
SNP are at increased
risk for experiencing a
venous thrombosis
event and would
benefit from
prophylactic
anticoagulant therapy
&/or preventative
measures (antiembolic stockings).

Note: ᵃ Results from Ferguson et al., (2010). Gene-nutrient interactions in the metabolic syndrome: single nucleotide
polymorphisms in ADIPOQ and ADIPOR1 interact with plasma saturated fatty acids to modulate insulin resistance. American
Journal of Clinical Nutrition, 91, 794-801. ᵇ Results from Murphy, M. Abbeduto, L. (2005). Indirect genetic effects and the early
language development of children with genetic mental retardation syndromes, the role of joint attention. Journal of Special Care
Practices, 18(1), 47-59. &Berne, E. (2001). Transactional analysis in psychotherapy. London: Souvenir. ᶜ Results from Sharma,
P., & Gohil, R. (2010). Genetic risk factors for venous thrombosis: the end of the beginning?. Expert Review of Cardiovascular
Therapy, 8(1), 11-13. doi:10.1586/erc.09.159
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Pharmacogenetics
Pharmacogenomics is the study of how genes affect individual drug responses. An
individual’s genetic makeup can result in alterations in genes that code for metabolizing
enzymes and drug targets. Through an analysis of an individual’s complete DNA structure,
the body’s response to medicines can be studied to predict therapeutic and adverse effects
(HGPI, 2010). Pharmaceutical interventions can be tailored to an individual to produce
more effective and safe medications when the genetic susceptibility of a drugs
pharmacokinetics are determined. The benefits of individualized drug therapy are
exceptionally profound for the treatment and management of disease conditions. Through
the analysis of human DNA/RNA molecules, proteins, and enzymes and the genes
associated with specific diseases, a stronger therapeutic response can be created, with drug
targets that are disease specific (HGPI, 2010). When beginning an individualized drug
regimen, genetic results can be analyzed to determine the most effective drug response
that can be elicited for a specific individual. Tailoring drugs to an individual’s genetic
composition can optimize therapeutic response to a drug while minimizing the risks of
adverse reactions to the agent. Pharmacogenetics focuses on identifying genotypes that
drive favorable or unfavorable drug responses (O’Malley, 2011). This can also lead to a
reduction in the cost of a therapeutic agent by lessening the risk associated with
prescribing ineffective drugs to certain genotypes. Currently, pharmacodynamics and
pharmacokinetics are based on anthropometric measurements and age (HGPI, 2010).
Using one’s genotype provides a more accurate measurement of how the body metabolizes
13

a drug and determines dosage requirements. In fact, the Federal Drug Administration
(FDA) has issued a warning that states, “drug outcomes are the function of genetic makeup
and response variance, and side effects and adverse outcomes can be significantly
controlled by prescribing based on a genetic profile” (O’Malley, 2011). Perhaps the most
important indication for receiving the correct medication the first dose would be to
eliminate the 100,000 deaths that occur annually as a result of pharmaceutical-geneticmismatch (HGPI, 2010). These deaths resulted from either drug accumulation of toxic
levels in the blood or the body’s inability to use the drug based on genetic factors. Other
topics to consider while examining the benefits of pharmacogenetics are the use of new
medications in clinical trials for drug discovery and development, vaccinations, and the
reduction of overall health care costs (HGPI, 2010). Genetic profiling allows researchers to
categorize individuals for clinical trials based on genotype, resulting in shorter clinical
trials and reduced number of subjects needed (O’Malley, 2011). Furthermore, with the use
of genetic profiling to identify individual variation in drug response, the time for drug
development has the potential to reduce from 10 to 12 years to 3 to 5 years (O’Malley,
2011).
Ethnopharmacology in Psychotropic Drugs
According to The Human Genome Project (2010), there are over 30 classes of drugs
identified which are metabolized by the liver. The rate and amount of metabolism is
influenced by DNA variations of cytochrome P450 genes. In the example of
14

ethnopharmacology (Shives, 2008), variations in the metabolism of psychotropic drugs are
found, based on ethnicity. When prescribing psychotropic medications in the treatment of
psychiatric disorders, differences in ethnic hepatic-biotransformation must be taken into
consideration. Individuals who possess high enzymatic activity metabolize these
medications at a very high rate, where as individuals with less or inactive enzymatic
activity metabolizes the medications much slower (Shives, 2008). Adverse drug events can
be a direct result of the rate and ability to metabolize medication. Literature reviewed by
Shives (2008) identified that a large percent of the Eastern Asian population are
considered “poor metabolizers”. Additionally, the same percentages of African Americans
have been found to metabolize these drugs at a slower rate, in comparison to Caucasians.
The resulting effect, shown in Table 2, can lead to an increased incidence of adverse effects
(Shives, 2008). In consideration of a specific drug, lithium, it has been found that these
particular ethnic groups also require reduced doses. Variations in plasma protein that
binds lithium result in accumulation of the drug in the blood. Therefore, a dosage reduction
is required to reduce the risk of lithium toxicity in the central nervous system (Shives,
2008).
Hepatic Metabolism of Anticoagulants
Hepatic pathways that metabolize anticoagulants are the latest trend in genetic
testing that combines an individual’s cellular environment with genetic vulnerability to
drug therapy. The FDA recommends that patients undergo genetic testing for alterations in
15

enzymatic activity prior to prescribing the treatment of the anticoagulant agent, warfarin
[Coumadin] (Lehne, 2010). When daily anitembolism therapy is necessary, dosage
adjustments should be considered in individuals with alterations in the cytochrome P4502C9 [CYP2C9] and Vitamin K epoxide reductase [VKORC1] (refer to Table 2). Warfarin is
used in the treatment for long-term prophylaxis of thrombosis formation, including
prevention of venous thrombosis, prevention of thrombosis during atrial fibrillation, and to
reduce the risk of recurrent transient ischemia attacks (Lehne, 2010). The enzyme CYP2C9
is responsible for warfarin metabolism; hence, individuals with alterations in this enzyme
metabolize the drug at a slower rate. Additionally, VKORC1 is the target enzyme that
warfarin inhibits, thus genetic alterations increase the enzyme’s sensitivity to warfarin.
Because warfarin has a narrow therapeutic index, these individuals are at greater risk for
warfarin-induced bleeding, which concludes that these individuals require a dosage
reduction (Limdi, Wiener, Goldstein, Acton, & Beasley, 2009).
In regards to genetic influence on drug responses, several European phenotypes,
shown in Table 3, demonstrate genetic tendencies to be slow metabolizers of
succinylcholine, resulting in a need for dosage adjustments (Lehne, 2010). As shown in
Table 4, approximately 52% of Caucasians are slow metabolizers of the drug isoniazid,
used in the treatment of tuberculosis (Lehne, 2010). In the treatment of cancer, Table 3
demonstrates that a small percentage of the United States population have genetic
alterations in alleles that slow the metabolism of the drug fluorouracil, a chemotherapeutic
agent used in the treatment of cancer for over 40 years (Lehne, 2010). In some cases, this
16

reduction in metabolism has resulted in death (Lehne, 2010). Lastly, Asians have been
found to have alterations in human leukocyte antigens [HLA-B 1502], which increases the
risk for developing life-threatening skin reactions when using the drug carbamazepine
[Tegretol] (refer to Table 4). The FDA states that tests are available to identify genetic
alterations in metabolism and recommends genetic screening prior to initiation of
treatment (Lehne, 2010).
Ethnic Variation in Biotransformation of Chemotherapeutic Agents
Ethnic variations in response to chemotherapeutic drugs in the treatment of
leukemia have been a focus of genetic susceptibility research. Displayed in Table 3, some
Caucasians possess genetic variations of the enzyme thiopurine methyltransferase (HGPI,
2010). This enzyme is responsible for breaking down chemotherapeutic agents for use in
the body. Genetic variations result in the inactivation of enzymatic activity that promotes
the breakdown and excretion of the drug. The inability to metabolize the drug results in
toxic blood levels of highly chemotaxic agents to remain in the body longer (HGPI, 2010).
Therefore, screening for the deficiency prior to administering this class of medications is
essential (HGPI, 2010).
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Table 2: Pharmacogenetic Interventions in Warfarin Users, and Eastern Asian and African American
Populations
Researcher

Population Studied
Eastern Asian

Genetic
Alteration
cytochrome P450

Pharmaceutical
Factor
psychotropic drugs,
especially lithium
(used in the
treatment of
psychotic disorders

Shives (2008)

Shives (2008)

African American

cytochrome P450

psychotropic drugs,
especially lithium
(used in the
treatment of
psychotic disorders

Lehne (2010)

Warfarin Users

cytochrome P4502C9 [CYP2C9]

warfarin
[Coumadin]

Vitamin K epoxide
reductase

(used in the
prevention of
thrombosis)

Findings
possess lower
enzymatic activity in
the metabolism of
psychotropic drugs
and require a
dosage reduction

possess lower
enzymatic activity in
the metabolism of
psychotropic drugs
and require a
dosage reduction

metabolize this drug
at slower rates than
current prescribing
guidelines follow,
and require dosage
adjustments to
decrease the risk of
warfarin induced
bleeding

Note: ᵃᵇ Results from Shives, L.R. (2008). Basic concepts of psychiatric-mental health nursing. Lippincott
Williams & Wilkins: Philadelphia, PA ᶜ Results from Lehne, R. A. (2010). Pharmacology for nursing care (7th
ed.). St. Louis: Saunders Elsevier.
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Table 3: Pharmacogenetic Interventions in Europeans, U.S. Populations, and Caucasians
Researcher
Lehne (2010)

Population
Studied
European (1 in
3500)

Genetic Alteration
butyrlcholinesterase
(enzyme)

Pharmaceutical
Factor
Succinylcholine
(used in
neuromuscular
blockade)

Lehne (2010)

HGPI (2010)

1 % of the U.S.
population

Caucasian

dihdropyrimidine
dehydrogenase
(enzyme)

thiopurine
methyltransferase
(enzyme)

Fluorouracil
(used in the
treatment of
cancer)

chemotherapeutic
agents
(used in the
treatment of
cancer)

Findings
reduced rates of
the enzyme
responsible for
the metabolism
of this drug,
requiring a
dosage reduction
to prevent
permanent
paralysis.
produce a poor
form of this
enzyme, which is
responsible for
metabolism of
the drug

results in
inactivation of
enzymatic
activity that
promotes the
breakdown and
excretion of this
drug, increasing
the risk for toxic
blood levels

Note: ᵃᵇ Results from Lehne, R. A. (2010). Pharmacology for nursing care (7th ed.). St. Louis: Saunders
Elsevier. ᶜ Results from HGPI, Human genome project information. (2010). U.S. Department of Energy
Genome Program's Biological and Environmental Research Information System (BERIS).
http://genomics.energy.gov.
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Table 4: Pharmacogenetic Interventions in Asian and Caucasian Populations
Researcher
Lehne (2010)

Population
Studied
Asian

Genetic
Alteration
human leukocyte
antigens
[HLA-B 1502]

Pharmaceutical
Factor
carbamazepine
[Tegretol]
(used in the
treatment of
seizures)

Lehne (2010)

Caucasian (1 in 14)

cytochrome P450

Morphine
(used in the
treatment of pain

Lehne (2010)

U.S. Caucasian

Nacetyltransferase2
(enzyme)

Isoniazid
(used in the
treatment of
tuberculosis)

Findings
produce this
unusual antigen
which increases
the risk for
developing lifethreatening skin
reactions when
using the drug

are unable to
convert codeine
into morphine (its
active form),
resulting in no
pain relief

2 different forms
of the enzyme:
52% were found
to be slow
metabolizers,
putting them at
risk for toxicity;
48% were found
to be rapid
metabolizers,
putting them at
risk for treatment
failure

Note: ᵃᵇᶜ Results from Lehne, R. A. (2010). Pharmacology for nursing care (7th ed.). St. Louis: Saunders
Elsevier.
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ECO-PHARMACO-GENETIC INTERVENTIONS
Hypertension in the African American Population
Currently, a gap in knowledge exists in the development and treatment of
hypertension associated with African Americans. The prevalence of hypertension in African
Americans is nearly twice as much compared to other races (Ambler & Brown, 1999). The
increasing incidence of hypertension in this population has influenced researchers to
investigate genetic variations and physiological differences among African Americans.
Ambler & Brown (1999) concluded that this population possesses unique genetic allele
expressions that may interact with environmental-behavioral conditions to increase blood
pressure. These characteristics include an elevated sensitivity of blood pressure to sodium
transport, with alterations in renal sodium handling (Ambler & Brown, 1999). Exposure to
environmental risk factors (Table 5), such as sedentary lifestyle, increased sodium and
caloric intake, and stress further influence these characteristics and associated
complications. In the treatment hypertension, Ambler & Brown (1999) examined the
response of antihypertensive therapy and gene variations in the rennin-angiotensinaldosterone system (RAAS). African Americans were found to be better responders to
diuretic and calcium channel blocker therapies, and less to ACE inhibitors. The authors
attributed these findings to the mechanism of action the therapies had on the RAAS. This
study demonstrated a correlation between polymorphisms in the rennin and atrial
natriuretic peptide genes and hypertension in African Americans (Ambler & Brown, 1999).
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Further clarifying these findings, an additional study conducted by Frazier et al. (2004)
examined therapeutic response to antihypertensive therapy in African American women.
The results concluded that variations in genes in the RAAS of this population were
responsible for the blood pressure response to diuretic therapy.
Percutaneous Interventions in Cardiovascular Disease
Knowledge of environmental stimuli that trigger disease susceptible genes can be
used in healthcare education to promote disease prevention and maintenance. Genetic
susceptibility in individuals with cardiovascular disease and comorbidities related to
complications from cardiac conditions are being explored for their potential to prevent
disease. More than 2 million people annually undergo cardiac procedures in the United
States (O’Malley, 2010). Genetic determinants of disease suggest that certain
polymorphisms of alleles can predetermine poor physiologic outcomes which increase the
likelihood of complications and the need for further therapeutic interventions (Frazier et
al., 2004). Genetic susceptibility for adverse events such as: thromboembolism, restenosis,
or death, exists in individuals who possess polymorphisms in prothrombin [G20210A] and
antithrombin III, as seen in Table 5. Prothrombin plays a significant role in hemostasis,
while antithrombin III keeps the hematologic system under control by inactivating clotting
factors (Frazier et al., 2004). A genetic disruption in either hematologic cascade can
potentially increase the risk of complications in individuals with cardiovascular disease
undergoing treatment. Therefore, the environmental components, or individual treatment
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options, can be determined based on genetic profiling for susceptibility to drug therapy
effectiveness.
Clopidogrel [Plavix] has been the antiplatelet drug of choice in the prevention of
stenosis of coronary stents (Lehne, 2010). A study conducted by O’Malley (2011)
determined that patients with alterations in the gene that is responsible for the metabolism
of Plavix, CYP2C19, are less likely to benefit from this drug therapy and are at increased
risk thrombotic events. Additionally, the study found that individuals with polymorphisms
in the enzyme PON1, required in the transformation of Plavix into an active metabolite,
experienced higher risk of thrombosis formation post-stent placement and use of the drug
(O’Malley, 2011). Genetic screening for these polymorphisms will lead to more
individualized planning, resulting in better patient outcomes regarding cardiac procedures
(Frazier et al., 2004). The monetary cost for invasive cardiac procedures is steep and the
associated emotional stress of undergoing a cardiac procedure can sometimes worsen the
condition (Caldwell, Arthur, Natarajan, & Anand, 2007). Identifying individuals susceptible
to targeted therapies, such as a new drug regimen or diet and lifestyle modifications, can
help decrease the emotional stress and healthcare cost of invasive procedures and
expensive drug therapies (Caldwell et al., 2007).
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Table 5: Eco-Pharmaco-Genetic Interventions in African American populations and Individuals
Undergoing Invasive Cardiac Procedures
Research
er
Ambler &
Brown
(1999)

Population
Studied
African
American

Genetic Alteration
renal sodium
handling
rennin-angiotensinaldosterone system
(RAAS)

Frazier et
al., (2004)

Pharmaceutical
Factor
antihypertensive
drugs
[diuretics,
calcium channel
blockers, ACE
inhibitors]

Environment
al Factor
sedentary
lifestyle
increased
sodium intake
increased
caloric intake
stress

Frazier et
al., (2004)
O’Malley
(2010)

Individuals
Undergoing
Cardiac
Procedures

prothrombin
(G20210A)

clopidogrel
[Plavix]

cardiac
procedures

antithrombin III

(used in the
prevention of
stenosis post
stent placement

percutaneous
intervention
[PCI, stent]

CYP2C19 (enzyme)
PON1 (activator
enzyme)

Coronary
Artery Bypass
Graft [CABG]

Findings
increased
sensitivity to
elevated blood
pressure, especially
in response to
favorable
environmental
triggers;
respond better to
diuretic or calcium
channel blocker
therapies & less to
ACE inhibitors

both cause
increased risk for
adverse events:
thromboembolism,
restenosis, or
death; determine if
patient is better
candidate for PCI or
CABG
inability to
metabolism drug or
convert to its active
form for use

Note: ᵃ Results from Ambler, S., & Brown, R. (1999). Genetic determinants of blood pressure regulation. Journal of
Cardiovascular Nursing, 13(4), 59. Retrieved from EBSCOhost. & Frazier, L., Turner S. T., Schwartz, G. L., Chapman,
A. B., & Boerwinkle, E. (2004). Multilocus effects of the renin angiotensin aldosterone system genes on blood
pressure response to a diuretic. Pharmacogenomics Nature, 4, 17-23. ᵇ Results from Frazier et al. (2004) Multilocus
effects of the renin angiotensin aldosterone system genes on blood pressure response to a diuretic.
Pharmacogenomics Nature, 4, 17-23. & O'Malley, P. (2011). Pharmacogenomics for the clinical nurse specialist--genetics, prescribing, and outcomes. Clinical Nurse Specialist: The Journal for Advanced Nursing Practice, 25(3),
110-112. doi:10.1097/NUR.0b013e3182170fc2.
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BARRIERS AND ETHICAL DILEMMAS TO GENETIC INTERVENTION
Barriers, Allocation and Access
Barriers to genetic determinants of lifestyle management regarding ecogenetic and
pharmacogenetic interventions include disparities in the availability of appropriate
nutritional or medication resources among different income levels, geographical locations,
and ethnic differences. Likewise, barriers in identifying and determining which gene
variations affect drug response can impact pharmaceutical efficacy. Genetic coding that
determines individualized drug therapy can potentially reduce the marketable populations
for pharmaceutical stakeholders and places limitations on drug therapy alternatives
available to consumers (HGPI, 2010).
Although genetic research is currently revealing lifestyle modifications and selective
drug therapy based on genetic variation, increasing concern exists about the accessibility of
resources. Molecular profiling technology, genetic sequencing and mapping, are currently
being used to expand genetic profiling and interventions; however, a financial foundation
for funding has not yet been established. So the questions are: do individuals wait for
technology to become cheaper? And when and where do we start screening (Sharma &
Gohil, 2010)? Therefore, as research progresses, there is an increased need for program
development focused on how and which individuals will obtain genotype-based resources.
One program in favor of resource accessibility, the Genetic Diseases Act in 1976, brought
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funding of state and federal programs to genetic services, and continues to represent the
importance of integrating genetics into health care services (Greco et al., 2007).
Exploration of future genetic studies that will alter lifestyles and interventions to
prevent or maintain disease will focus on mitigating questions pertaining to access of
genetic testing and outcomes. The new wave of genetics comes with risks of discrimination
in finances, employment and insurance (O’Malley, 2011). To begin with, the genetic
community lacks consistency in determining if intervention and testing is made available
only to individuals who have the financial means. There is also no clear definition for how
health insurance programs will be impacted based on genetic profiling, which poses major
ethical and financial implications to genetic use. Other barriers to enacting genetic lifestyle
management principles include cultural beliefs, individual access to health care services,
and genetic screening, as well as employment opportunities and education of health care
providers in regards to genetic interventions. The moral and ethical duty of individuals to
the community is also a concern where environmental health issues can influence
interventions, regardless of personal beliefs. Health care institutions and professionals
must be prepared to put concepts related to genetic disease management to use for
consumer health to be initiated (Frazier et al., 2004).
Cambridge Genetics Knowledge Park
Currently, The Cambridge Genetics Knowledge Park of the United Kingdom (CGKP)
is investing substantial time and money to develop programs that will lead to the
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involvement of the general public with ethical, legal, and societal issues associated with
advances in human genetics (Dutta, Brice, & Wallace, 2005). The ethical and social issues
that are brought forth are not necessarily new to the health care industry. Ethical issues
associated with human genetics may include individual obligation for genetic susceptibility
testing and to community/family awareness. Societal issues arise from individuals having
equal access to care and appropriate allocation of resources (Frazier et al., 2004). In an
effort to minimize such dilemmas, this organization has included experts in the fields of
philosophy, law, health economics and social science, epidemiology, molecular biology, and
clinical and public health medicine in genetic decision making (Dutta et al., 2005).
Ultimately, collaboration across the domains of ethicists, scientists, philosophers,
individuals, insurers, and employers will guide genetic use in health care. The CGKP is also
working with the insurance industry to determine the basis for insurance premiums based
on genetic screening profiles. GINA, the act passed disabling insurance companies from
discriminating or raising premiums based on genetic profiles, will protect individuals from
discrimination based on genetic findings. Additionally, the CGKP is training specialists to
further genetics education to the next generation (Dutta et al., 2005). The organization
researched the current knowledge level of a wide variety of healthcare providers, as well as
patients, to assess the needs of different groups for education in genetics, and to implement
effective ways of providing the necessary knowledge and skills based on those findings
(Dutta et al., 2005).
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Ethical Principles of Autonomy and Justice
When considering the principle of autonomy, or self-determination, genetic
interventions are described as services offered to individuals as goods for private
consumption, to be accepted or refused as individuals see it (Buchanan et al., 2000).
Buchanan et al. (2000) argues that this personal service model honors only those who are
in a position to chose or afford genetic interventions, and not necessarily those affected
who may be in need. However, with proper allocation of resources and the incorporation of
laws and insurance policies, all of society may benefit. With new discoveries, a public
health model will guide genetic interventions. The interventions will become the norm of
health care services, which will affect the overall genetic health of society.
Equal opportunity must be examined when considering the principle of justice in
the use of genetic intervention. To ensure justice, no individual must be discriminated upon
by characteristics such as ethnicity, religion, race, or gender. Rather than being excluded
for these characteristics as with discrimination, individual characteristics will
guide/individualize interventions. Another valid point stated by Buchanan et al. (2000) is
Norman Daniel’s theory of just health care. This theory proposes that a “just health care
system should strive to remove barriers to opportunity that are due to disease” (Buchanan
et al., 2000). Genetic interventions will be an important means of eliminating barriers to
opportunity posed by disease.
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IMPLICATIONS FOR GENETICS IN NURSING PRACTICE
Genetics in nursing practice will focus on health issues, genetic conditions, and
diseases or susceptibilities to diseases caused or influenced by genes in interaction with
other risk factors that may require nursing care (Greco et al., 2007). The International
Society for Nurses in Genetics (ISONG) of the American Nurses Association, established in
1988, is responsible for defining and developing the scope of professional nursing practice
in genetics for nurses globally (Greco et al., 2007). ISONG’s vision of “caring for people’s
genetic health” has been the foundation for defining knowledge and the scope of genetics
nursing practice. Credentialing for the practice of genetics in nursing care is available
through the Genetic Nursing Credentialing Commission. Although genetic nursing may
occur in any health care setting, credentialing is currently reserved for nurses who spend
at least 50% of their time providing genetic-related nursing care (Greco et al., 2007). The
delivery of care will be based on the nursing care model, with the incorporation of genetics
into assessment, diagnosis, planning, implementation, and evaluation. As with other
practices in the discipline, genetic nursing practice will consist of basic and advanced level
care degrees. The future of basic genetic knowledge in nursing will provide a role in the
delivery of genetic services to all licensed registered nurses, as society becomes more
aware of the influence of genetics regarding health and disease (Greco et al., 2007).
Responsibilities in nursing practice will use genetic information in health
promotion and teaching, coordination of care, resource referral, consultation, advocating,
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and counseling. Nurses will assist individuals in becoming informed consumers of the
established plan care, as well as identifying and evaluating cost-to-benefit factors, safety,
and availability of interventions (Greco et al., 2007). The challenge for nursing in
personalized health care lies in the increasing complexity of healthcare associated with the
expansion of genetic knowledge (Greco et al., 2007). Nurses must be prepared to
incorporate individual genotype into the delivery of care. Strategies to overcome this
challenge focus on an interdisciplinary approach, which is reliant on the overlapping skills
and knowledge of other disciplines in the implementation of care (Greco et al., 2007). The
National Coalition for Health Professionals in Genetics has defined core competencies that
provide a framework for educational programs in nursing. These competencies address the
biological, ethical, and psychosocial impact of genetics in nursing practice (Greco et al.,
2007). To be prepared for the challenges of genetics, nurses must participate in addressing
ethical issues and applying genetic research to practice, in collaboration with other team
members. Nurses will need to stay current with information to provide families and
patients education about disease process and treatment, while incorporating knowledge of
the interaction of genetic and environmental factors in disease progression (Frazier et al.,
2004). Lastly, as advances in human genetics expand rapidly, practicing nurses must
continue to increase technological and educational competencies in the delivery of nursing
care (Greco et al., 2007).
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CONCLUSIONS
Results from this literature review have revealed individualized interventions based
on genetic profiles. The Human Genome Project (2010) has been the most recent
foundation for discovery of genetic components, and has provided a basis for current and
future research in the molecular science field. Genetic testing poses many challenges to
society, and therefore should rely on genetic counseling to determine its appropriateness.
Therapeutic interventions have been discussed, based on ecogenetics and
pharmacogenetics. Understanding the etiology of disease from a multifactorial standpoint
will open the door to the next generation of therapeutic interventions (Ambler & Brown,
1999). In example, when considering genetic vulnerability and environmental factors in
metabolic syndrome phenotypes, screening individuals for polymorphisms in the
adiponectin gene will help identify those that would likely benefit from modification of
dietary fat intake. Understanding metabolic related polymorphism and its interaction with
dietary fatty acids assists in identifying causes of insulin-resistance in individuals with this
genotype. For children with fragile X syndrome, environmental factors that decrease
sensory stimulation while still promoting socially-adaptive behaviors will decrease the
extent of expression. Identifying children at early stages in the disease to intervene with
appropriate environments will halt the progression. Genetic vulnerability in cardiovascular
disease must be considered when implementing treatment options and establishing plan of
care. Individuals must be screened for polymorphisms in the prothrombin and
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antithrombin III nucleotides prior to percutaneous interventions or coronary artery bypass
to determine the safest treatment option. These polymorphisms are not only specific to
cardiovascular disease treatment procedures. Individuals, such as the traveling population,
with these genetic alterations may encounter favorable environmental triggers, extended
flights, which also increase their risk for experiencing a thromboembolic event.
With the use of pharmacogenetics, health care models will be developed to create
more effective drug therapy regimens, while decreasing the risk of adverse events.
Uncovering genetic variance has demonstrated the differences in ethnic variations, as well
as single nucleotide polymorphisms that can affect human response to drug therapy.
Identification of single nucleotide polymorphisms provides a framework to understand
genetic variation in drug response to create targeted individualized drug therapy (Ambler
& Brown, 1999). Variations in the hepatic metabolism and the renal system illustrate that
African Americans are less likely to respond to specific treatments based on genetic
influence, and would benefit through selective classes of drug therapy. Ethnic variations in
hepatic metabolism were also analyzed in the East Asian populations and concluded that
these individuals would benefit from dosage reductions in psychotropic drugs. With the
number of adverse events and decreased response to drug therapy occurring from
improper identification to genetic profiling, pharmacogenetics must be implemented to
improve health outcomes.
Future studies will need to establish guidelines, roles, and career opportunities for
health care professionals that incorporate the new evidence pertaining to genetic
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discoveries and health outcomes into practice. There is also a need to continue research in
environmental triggers associated with expression of susceptibility genes, as well as how
genes interact with other genes to promote disease. Genes encode instructions on how to
make proteins; therefore, proteomics, or studies that explore protein structure and activity
will need to be focused on in future research. Millions of alterations in single nucleotides,
single nucleotide polymorphisms, must be identified to determine their involvement in
drug response (HGPI, 2010). Universal [standardized] protocols will be replaced with
treatment options based on genetic profiles. Lastly, an in-depth analysis of ethical-decision
making must be researched pertaining to the use of genetic interventions for treatment
versus enhancement. With further research, it can be predicted that genetics will assist in
closing the therapeutic gap between disease and treatment.
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